TL;DR: A 2026 randomized feasibility trial in Nature Medicine found that gait-synchronized adaptive deep brain stimulation was feasible and safe in 5 people with Parkinson’s disease, with early findings of improved gait symmetry, lower variability, and fewer reported falls than continuous stimulation. Key Findings 5 Parkinson’s patients: The 1-center feasibility trial enrolled people with Parkinson’s …
TL;DR: A 2026 review in Drug Design, Development and Therapy argued that glucagon-like peptide-1 (GLP-1) receptor agonists, drugs that mimic a metabolic hormone involved in glucose control, have credible brain-protection mechanisms, but clinical evidence for neurological disorders remains mixed. Key Findings 15-page review: Li et al. summarized GLP-1 receptor agonist mechanisms and evidence across neurodegenerative, …
TL;DR: A 2026 preprint in bioRxiv found that Magnetic Resonance Artificial Intelligence Velocimetry (MR-AIV), a physics-informed AI method for estimating brain fluid transport, produced stable velocity and permeability maps across several modeling stress tests. Key Findings Brain-fluid target: MR-AIV estimates three-dimensional velocity, pressure, and permeability fields from dynamic contrast-enhanced MRI. 10-region initialization: A universal, anatomically …
TL;DR: A 2026 study in Journal of Neuroinflammation found that people with multiple sclerosis had altered peripheral immunoglobulin repertoires, and several disease-modifying treatments shifted B-cell repertoire patterns after 6 months. Key Findings 33 MS patients: Researchers analyzed peripheral B-cell immunoglobulin heavy-chain repertoires in 33 people with MS and 10 healthy controls. 196.1 million sequences: The …
TL;DR: A 2026 study in Open Life Sciences reported that ELAVL1, an RNA-binding protein, protected stressed retinal cells by maintaining WDR36 protein, reducing p53 activation, and limiting calcium overload in cell and acute mouse pressure-injury models. Key Findings OGD/R cell stress: Oxygen-glucose deprivation/reoxygenation reduced ELAVL1 and WDR36 protein in R28 retinal precursor cells. mRNA-protein mismatch: …
TL;DR: A 2025 study in Neurology used a Kaiser Permanente target-trial emulation and found that starting a statin was not linked to higher or lower Alzheimer disease or related dementia incidence after the first year. The first-year diagnosis increase likely reflected more medical contact after a new prescription. Key Findings No difference after year one: …
TL;DR: A 2026 preprint in medRxiv reported that a urine beta-amyloid protein test kit separated mild cognitive impairment or Alzheimer’s disease from healthy controls in a multicenter Chinese sample, while a 51,187-person community screen showed age-related positive rates. Key Findings 898-person validation sample: The multicenter case-control arm included 266 healthy controls, 167 people with mild …
TL;DR: A 2026 computational study in PLOS One used GEO Alzheimer’s datasets, 130 machine-learning models, and molecular simulations to identify eight candidate genes that may sit in a trichostatin A-related Alzheimer’s disease network. Key Findings 949 predicted TSA targets: The analysis started with predicted human protein targets for trichostatin A, a histone deacetylase inhibitor. Five …
TL;DR: A 2026 study in Brain, Behavior, & Immunity – Health reported that Theiler’s murine encephalomyelitis virus (TMEV), a mouse neurotropic virus, infected substantia nigra dopamine neurons and produced Parkinson’s-like motor deficits in mice. Key Findings 13 TMEV mice vs 14 controls: The main behavioral experiment compared unilateral TMEV injection into the substantia nigra with …
TL;DR: A 2026 preprint on medRxiv found that older adults with mild-cognitive-impairment-level scores showed different resting facial action patterns than healthy controls, especially upper lip raiser, lip tightener, and lip suck measures. Key Findings MCI-level comparison: The study included 45 older adults and compared 31 participants in the MCI-level group with 14 healthy controls. MoCA-defined …
